CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data

Key Takeaways CTMX shares jumped 44% after strong phase I expansion data for Varseta-M in late-line metastatic CRC.CTMX reported response rates rising from 6% to 32% across dose levels, with disease control reaching 88%.CTMX plans FDA talks to align on a registrational CRC study and plans new studies with Avastin combos.Shares of CytomX Therapeutics (CTMX) soared 44.2% on Monday after the company reported positive phase I expansion data for its EpCAM-targeting PROBODY ADC, varsetatug masetecan (Varseta-M), ...